Psoriatic arthritis patients who stay on 1 anti-TNFi drug fare better

04/26/2013 | Family Practice News

Patients with psoriatic arthritis who switched to a second anti-tumor necrosis factor inhibitor drug had lower drug-survival rates at three years compared with those who remained on their first medication, researchers in Norway found. Switchers also showed much poorer responses in factors such as Disease Activity Score-28 remission and American College of Rheumatology-50 response than non-switchers. The findings were published in the journal Annals of the Rheumatic Diseases.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
CONTRACT - Education Consultants
Confidential
East Coast, Phoenix, Los Angeles, SL_Multiple Locations
Inside Sales Representative
Apperson, Inc.
Multiple Locations, SL_Multiple Locations
Product Marketing Manager
Apperson, Inc.
Charlotte, NC
Business Development Analyst
Insight Education Group
Los Angeles, CA
Marketing Manager
Insight Education Group
Washington, DC or Los Angeles, CA